Juniper Pharmaceuticals, Inc. Common Stock
JNP
JNP was delisted on the 13th of August, 2018.
36 hedge funds and large institutions have $9.93M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 16 reducing their positions, and 6 closing their positions.
5% less funds holding
Funds holding: 38 → 36 (-2)
26% less capital invested
Capital invested by funds: $13.5M → $9.93M (-$3.57M)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
50% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 16
59% less call options, than puts
Call options by funds: $156K | Put options by funds: $384K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
+$354K |
| 2 |
GF
Gabelli Funds
Rye,
New York
|
+$206K |
| 3 |
SIM
Spark Investment Management
New York
|
+$108K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$77.5K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$67.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
-$967K |
| 2 |
JIR
James Investment Research
Alpha,
Ohio
|
-$815K |
| 3 |
DMK
David M. Knott
|
-$568K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$127K |
| 5 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
-$91K |
JNP Hedge Fund Activity: Q3 2014 in Review
36 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q3 2014, worth a combined $9.93M — down 26% from $13.5M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of JNP and 4 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 8 added.
The largest buyer was LSV Asset Management, adding an estimated $354K. The largest seller was Wedge Capital Management, exiting entirely with an estimated $967K sold.
- 36 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q3 2014, down from 38 in Q2 2014.
- Funds reported $9.93M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q3 2014, down 26% quarter-over-quarter.
- 4 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q3 2014 and 6 closed out, a net change of -2 holders.
- The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q3 2014 was LSV Asset Management, an estimated $354K added.
- The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q3 2014 was Wedge Capital Management, an estimated $967K sold.
Based on aggregated 13F filings for Q3 2014.